Bayer Paying $14.2 Billion To Buy Consumer Care Business Of Merck; Both Companies To Collaborate On Developing, Marketing New Drugs

  @MikeObel m.obel@ibtimes.com on
Merck's fourth-quarter expectations top expectations
Merck's fourth-quarter expectations top expectations

Bayer AG (FRA:BAYG) said Tuesday it will pay $14.2 billion for the consumer care business of Merck & Co. Inc. (NYSE:MRK), giving the giant German chemical and pharmaceutical company global trademark and prescription rights to such well-known brands as Claritin allergy medicine, Coppertone suntan lotion and Dr. Scholl's foot care products.

Merck, which is based near Philadelphia, said it expects after-tax proceeds of between $8 billion and $9 billion from the sale, which is expected to close later this year. The U.S. company will use the proceeds to fund development of such medicines as MK-3475, a prospective melanoma cancer drug.

In addition, the two companies announced a worldwide clinical development collaboration to market and develop drugs for cardioavscular disease, including hypertension drug Adempas.

 

Join the Discussion
Nintendo's Newest Kirby Game Is A Total Detour
Nintendo's Newest Kirby Game Is A Total Detour
Fitbit's First Activity Watch Falls Short
Fitbit's First Activity Watch Falls Short
Dying Light Is The Spiritual Successor To 'Dead Island'
Dying Light Is The Spiritual Successor To 'Dead Island'
The Last Mitsubishi Evolution
The Last Mitsubishi Evolution
The i8 Is Proof BMW Should Make More Mid-Engined Cars
The i8 Is Proof BMW Should Make More Mid-Engined Cars
QD Vision Shows Off Cheap 4K TVs
QD Vision Shows Off Cheap 4K TVs

More Video